Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682639 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT04682639: Completed Phase 2 study of Eosinophilic Esophagitis, sponsored by Pfizer.
NCT04682639 is a Phase 2 study of Eosinophilic Esophagitis that has completed, run by Pfizer. The registered enrollment target is 108 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04682639, a Phase 2 study of Eosinophilic Esophagitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
Primary Outcome
Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Etrasimod
Study Locations (20)
Alabama
- Clinical Research Center of Alabama, LLC - Birmingham
- GastroHealth - St. Vincent's East - Birmingham
- Digestive Health Specialists - Dothan
- Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only) - Dothan
- Dothan Surgery Center (Colonoscopy Location) - Dothan
- Pulmonary Associates (PFT Procedure Only, Second Location ) - Dothan
- Flowers Hospital (PFT Procedure Only) - Dothan
- Avant Research Associates, LLC - Huntsville
- Crestwood Medical Center - Huntsville
- Baily Cove Eye Care - Huntsville
- Madison Surgery Center - Madison
- Alabama Eye MD - Vestavia Hills
Arizona
- Arizona Retina Institute/ Phoenix Retina Associates(OCT) - Peoria
- SimonMed Imaging (Imaging) - Peoria
- Arizona Digestive Health - Sun City - Sun City
- Sun City Endoscopy Center (Endoscopy) - Sun City
Arkansas
- Little Rock Eye Clinic - Little Rock
- Four Seasons Allergy and Asthma - Little Rock
- Applied Research Center of Arkansas - Little Rock
- Premier Gastroenterology Endoscopy Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 2 |
What the finished NCT04682639 record still lists
NCT04682639 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04682639 names 20 study sites across 3 states, led by Alabama, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04682639 about?
NCT04682639 is a clinical study titled "A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis". The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
What is the current status of trial NCT04682639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2020-12-15. Estimated completion is 2023-06-30.
What conditions does trial NCT04682639 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT04682639?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT04682639?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04682639 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04682639's enrollment target sits among peer trials
108 17th of 44 higher than 28 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI